Table 2 Discontinuation from treatment... | American Society of Hematology

Table 2

Discontinuation from treatment

Reason, n (%)	IM + DAS resistant (n = 37)	IM + DAS intolerant (n = 50)	IM + NI resistant (n = 27)	IM + DAS ± NI (n = 4)*	Total (n = 118)
Discontinued treatment	31 (84)	34 (68)	16 (59)	3 (75)	84 (71)
Unsatisfactory response (efficacy)	12 (32)	7 (14)	5 (19)	1 (25)	25 (21)
AE	6 (16)	15 (30)	3 (11)	0	24 (20)
Disease progression	8 (22)	4 (8)	6 (22)	2 (50)	20 (17)
Death	2 (5)	2 (4)	0	0	4 (3)
Patient request	0	2 (4)	1 (4)	0	3 (3)
Lost to follow-up	2 (5)	0	0	0	2 (2)
Investigator request	0	0	1 (4)	0	1 (1)
Protocol violation	0	1 (2)	0	0	1 (1)
Other†	1 (3)	3 (6)	0	0	4 (3)

Reason, n (%)	IM + DAS resistant (n = 37)	IM + DAS intolerant (n = 50)	IM + NI resistant (n = 27)	IM + DAS ± NI (n = 4)*	Total (n = 118)
Discontinued treatment	31 (84)	34 (68)	16 (59)	3 (75)	84 (71)
Unsatisfactory response (efficacy)	12 (32)	7 (14)	5 (19)	1 (25)	25 (21)
AE	6 (16)	15 (30)	3 (11)	0	24 (20)
Disease progression	8 (22)	4 (8)	6 (22)	2 (50)	20 (17)
Death	2 (5)	2 (4)	0	0	4 (3)
Patient request	0	2 (4)	1 (4)	0	3 (3)
Lost to follow-up	2 (5)	0	0	0	2 (2)
Investigator request	0	0	1 (4)	0	1 (1)
Protocol violation	0	1 (2)	0	0	1 (1)
Other†	1 (3)	3 (6)	0	0	4 (3)

IM indicates imatinib; DAS, dasatinib; and NI, nilotinib.

Includes 3 patients who previously received all 3 inhibitors and 1 patient with NI intolerance.

Includes patient noncompliance (n = 2), lack of finances (n = 1), and started chemotherapy for gastric adenocarcinoma (n = 1).